{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:17:54Z","timestamp":1792001874830,"version":"4.4.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005891","name":"State Administration of Traditional Chinese Medicine of the People\u2019s Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005891","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Shensong Yangxin (SSYX), a standardized Chinese preparation, is widely utilized in arrhythmia treatment. This research sought to assess the clinical advantages of SSYX for persistent atrial fibrillation (PsAF).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched seven databases and two registries to identify randomized controlled trials (RCTs) assessing SSYX as an adjunctive treatment for PsAF. We assessed methodological quality with the Cochrane Risk of Bias Tool 2.0, and conducted meta-analyses with RevMan 5.4.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The meta-analysis incorporated ten RCTs enrolling 1,713 patients with PsAF. SSYX combined with conventional treatments (CTs) significantly lowered the recurrence of AF compared to CTs alone (risk ratio [<jats:italic>RR<\/jats:italic>] = 0.65, 95% conffdence interval [<jats:italic>CI<\/jats:italic>] 0.56 to 0.75, <jats:italic>P<\/jats:italic> &amp;lt; 0.001). The results also showed that SSYX contributed to the reduction of left atrial diameter (<jats:italic>MD<\/jats:italic> = \u22121.41, 95% <jats:italic>CI<\/jats:italic> -2.48 to \u22120.34, <jats:italic>P<\/jats:italic> &amp;lt; 0.001) and P-wave dispersion (<jats:italic>MD<\/jats:italic> = \u221210.37, 95% <jats:italic>CI<\/jats:italic> -17.23 to \u22123.5, <jats:italic>P<\/jats:italic> = 0.003). Safety analysis revealed that the combination of SSYX and CTs decreased adverse reaction incidence (<jats:italic>RR<\/jats:italic> = 0.54, 95% <jats:italic>CI<\/jats:italic> 0.32 to 0.90, <jats:italic>P<\/jats:italic> = 0.02). The certainty of evidence was graded as moderate to low.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>SSYX showed potential in preventing AF recurrence in PsAF patients. Nevertheless, these preliminary findings require validation through more rigorously designed trials, given methodological limitations impacting evidence certainty.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251008974<\/jats:ext-link>, identifier CRD420251008974.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1620340","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T05:46:08Z","timestamp":1750225568000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of shensong yangxin capsules for persistent atrial fibrillation: a Systematic Review and meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"16","author":[{"given":"Yifan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuding","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runa","family":"A","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"OuYang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuye","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa2029980","article-title":"Cryoablation or drug therapy for initial treatment of atrial fibrillation","volume":"384","author":"Andrade","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1093\/eurheartj\/ehw564","article-title":"Contemporary management of patients undergoing atrial fibrillation ablation: in-hospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term registry","volume":"38","author":"Arbelo","year":"2017","journal-title":"Eur. Heart J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3760\/cma.j.cn113859-20211224-00264","article-title":"Atrial fibrillation: current understanding and treatment recommendations (2021)","volume":"26","author":"Association","year":"2022","journal-title":"Chin. J. Card. Arrhyth"},{"key":"B4","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1001\/jama.2019.0335","article-title":"Effect of catheter ablation vs antiarrhythmic medication on quality of life in patients with atrial fibrillation: the CAPTAF randomized clinical trial","volume":"321","author":"Blomstr\u00f6m-Lundqvist","year":"2019","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41572-022-00347-9","article-title":"Atrial fibrillation","volume":"8","author":"Brundel","year":"2022","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e010435","DOI":"10.1161\/circep.121.010435","article-title":"P wave parameters and indices: a critical appraisal of clinical utility, challenges, and future research-a consensus document endorsed by the international society of electrocardiology and the international society for holter and noninvasive electrocardiology","volume":"15","author":"Chen","year":"2022","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"572","DOI":"10.3760\/cma.j.cn112148-20230416-00221","article-title":"Chinese guidelines for the diagnosis and treatment of atrial fibrillation","volume":"51","author":"Chinese Society of Cardiology","year":"2023","journal-title":"Chin. J. Cardiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.jacc.2020.02.025","article-title":"Atrial fibrillation: JACC council perspectives","volume":"75","author":"Chung","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1093\/eurheartj\/ehae291","article-title":"Catheter ablation for persistent atrial fibrillation: patterns of recurrence and impact on quality of life and health care utilization","volume":"45","author":"Crowley","year":"2024","journal-title":"Eur. Heart J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3760\/cma.j.issn.1674-4756.2013.20.021","article-title":"Effect of Shensong Yangxin Capsule on p-wave dispersion and NT-proBNP in patients with persistent atrial fibrillation","volume":"40","author":"Du","year":"2013","journal-title":"Chin. J. Prac. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1136\/heartjnl-2019-315174","article-title":"Left atrial dimension and cardiovascular outcomes in patients with and without atrial fibrillation: a systematic review and meta-analysis","volume":"105","author":"Froehlich","year":"2019","journal-title":"Heart"},{"key":"B13","doi-asserted-by":"publisher","first-page":"156555","DOI":"10.1016\/j.phymed.2025.156555","article-title":"Natural products alleviate atrial fibrillation by modulating mitochondrial quality control","volume":"140","author":"Ge","year":"2025","journal-title":"Phytomedicine"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.3969\/j.issn.1001-1528.2018.11.009","article-title":"Clinical efficacy of Shensong Yangxin Capsules combined with valsartan capsules in patients with hypertension complicated by persistent atrial fibrillation","volume":"40","author":"He","year":"2018","journal-title":"Chin. Tradit. Pat. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.13193\/j.issn.1673-7717.2024.06.018","article-title":"Effects of Shensong Yangxin Capsule combined with sacubitril\/valsartan on hs-CRP, BNP, Ang\u2161 and cardiac function in the treatment of paroxysmal atrial fibrillation complicated with chronic heart failure","volume":"42","author":"He","year":"2024","journal-title":"Chin. Arch. Tradi Chin. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1093\/eurheartj\/ehae532","article-title":"Atrial tachyarrhythmia prevention by Shensong Yangxin after catheter ablation for persistent atrial fibrillation: the SS-AFRF trial","volume":"45","author":"Huang","year":"2024","journal-title":"Eur. Heart J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11655-018-2578-1","article-title":"Chinese medicine Shensong Yangxin Capsule ameliorates myocardial microcirculation dysfunction in rabbits with chronic myocardial infarction","volume":"27","author":"Jiang","year":"2021","journal-title":"Chin. J. Integr. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.3969\/j.issn.1008-8849.2017.25.012","article-title":"Observation on the efficacy of Shensong Yangxin Capsule combined with amiodarone in cardioverting early persistent atrial fibrillation after radiofrequency ablation","volume":"26","author":"Jin","year":"2017","journal-title":"Mod. J. Integr. Tradi Chin. West Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/cir.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"B20","doi-asserted-by":"publisher","first-page":"809","DOI":"10.3390\/jcm14030809","article-title":"Clinical, electrocardiographic and echocardiographic predictors of atrial fibrillation recurrence after pulmonary vein isolation","volume":"14","author":"Karanikola","year":"2025","journal-title":"J. Clin. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1161\/circresaha.120.316340","article-title":"Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights","volume":"127","author":"Kornej","year":"2020","journal-title":"Circ. Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1186\/s12889-022-14403-2","article-title":"Global, regional, and national burden of disease study of atrial fibrillation\/flutter, 1990-2019: results from a global burden of disease study, 2019","volume":"22","author":"Li","year":"2022","journal-title":"BMC Public Health"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1340855","DOI":"10.3389\/fphar.2024.1340855","article-title":"A review of chemotherapeutic drugs-induced arrhythmia and potential intervention with traditional Chinese medicines","volume":"15","author":"Li","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.19381\/j.issn.1001-7585.2020.08.021","article-title":"Observation on the efficacy of Shensong Yangxin Capsules combined with valsartan capsules in the treatment of hypertension complicated by persistent atrial fibrillation","volume":"33","author":"Li","year":"2020","journal-title":"J. Med. Theor. Prac."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo","year":"2018","journal-title":"Stat. Methods Med. Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.2147\/dddt.S182834","article-title":"Shensong Yangxin capsule reduces atrial fibrillation susceptibility by inhibiting atrial fibrosis in rats with post-myocardial infarction heart failure","volume":"12","author":"Ma","year":"2018","journal-title":"Drug Des. Devel Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ijcard.2020.11.019","article-title":"Real-world experience with implantable loop recorder monitoring to detect subclinical atrial fibrillation in patients with cryptogenic stroke: the value of p wave dispersion in predicting arrhythmia occurrence","volume":"327","author":"Marks","year":"2021","journal-title":"Int. J. Cardiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"391","DOI":"10.7661\/j.cjim.20210201.100","article-title":"Clinical application guidelines for the treatment of coronary heart disease with Chinese patent medicines (2020)","volume":"41","author":"Medicines","year":"2021","journal-title":"Chin. J. Integr. Tradi West Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e13771","DOI":"10.1111\/ijcp.13771","article-title":"Atrial fibrillation pattern, left atrial diameter and risk of cardiovascular events and mortality. A prospective multicenter cohort study","volume":"75","author":"Menichelli","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1001\/jama.2019.0693","article-title":"Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial","volume":"321","author":"Packer","year":"2019","journal-title":"JAMA"},{"key":"B31","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1111\/jce.14042","article-title":"Natural course of acquired pulmonary vein stenosis after radiofrequency ablation for atrial fibrillation-Is routine follow-up imaging indicated or not?","volume":"30","author":"Schoene","year":"2019","journal-title":"J. Cardiovasc Electrophysiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jep.2014.09.035","article-title":"Shensong Yangxin Capsule prevents diabetic myocardial fibrosis by inhibiting TGF-\u03b21\/Smad signaling","volume":"157","author":"Shen","year":"2014","journal-title":"J. Ethnopharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/eurheartj\/ehu359","article-title":"Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial","volume":"36","author":"Steinberg","year":"2015","journal-title":"Eur. Heart J."},{"key":"B35","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B36","doi-asserted-by":"publisher","first-page":"251","DOI":"10.13193\/j.issn.1673-7717.2020.02.062","article-title":"Effects of Shensong Yangxin Capsule with valsartan on sinus rhythm maintenance and left atrial function when treating paroxysmal atrial fibrillation","volume":"38","author":"Tuo","year":"2020","journal-title":"Chin. Arch. Tradi Chin. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1161\/circulationaha.123.064959","article-title":"Safety and effectiveness of pulsed field ablation to treat atrial fibrillation: one-year outcomes from the MANIFEST-PF registry","volume":"148","author":"Turagam","year":"2023","journal-title":"Circulation"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur. Heart J."},{"key":"B39","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"993","DOI":"10.3389\/fphar.2020.00993","article-title":"Shensong Yangxin protects against metabolic syndrome-induced ventricular arrhythmias by inhibiting electrical remodeling","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"154086","DOI":"10.1016\/j.phymed.2022.154086","article-title":"Shensong Yangxin attenuates metabolic syndrome-induced atrial fibrillation via inhibition of ferroportin-mediated intracellular iron overload","volume":"101","author":"Yang","year":"2022","journal-title":"Phytomedicine"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.3760\/cma.j.issn.1008-6706.2014.11.030","article-title":"Effect of Shensong Yangxin Capsule on plasma high-sensitivity C-reactive protein and N-terminal pro-brain natriuretic peptide levels after cardioversion in patients with persistent atrial fibrillation","volume":"11","author":"Yu","year":"2014","journal-title":"Chin. J. Prim. Med. Pharm."},{"key":"B43","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3969\/j.issn.1671-6450.2023.01.002","article-title":"Effect of Shensong Yangxin Capsules on left ventricular function and quality of life in patients with persistent atrial fibrillation after radiofrequency ablation","volume":"22","author":"Zhang","year":"","journal-title":"J. Diffic. Compl Cas."},{"key":"B44","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2147\/dddt.S392328","article-title":"Shensong Yangxin Capsule reduces the susceptibility of arrhythmia in db\/db mice via inhibiting the inflammatory response induced by endothelium dysfunction","volume":"17","author":"Zhang","year":"","journal-title":"Drug Des. Devel Ther."},{"key":"B45","first-page":"4119","article-title":"Clinical practice guideline of Chinese medicine for acute myocardial infarction","volume":"36","author":"Zhang","year":"2021","journal-title":"Chin. J. Tradi Chin. Med. Pharm."},{"key":"B46","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4103\/0366-6999.197997","article-title":"Effect of Shensong Yangxin on the progression of paroxysmal atrial fibrillation is correlated with regulation of autonomic nerve activity","volume":"130","author":"Zhao","year":"2017","journal-title":"Chin. Med. J. Engl."},{"key":"B47","doi-asserted-by":"publisher","first-page":"5185","DOI":"10.3892\/mmr.2016.5203","article-title":"Shensong Yangxin capsules prevent ischemic arrhythmias by prolonging action potentials and alleviating Ca2+ overload","volume":"13","author":"Zhao","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.3870\/j.issn.1004-0781.2019.08.009","article-title":"Adjuvant treatment of 60 cases of early recurrence after radiofrequency ablation for atrial fibrillation with Shensong Yangxin Capsules","volume":"38","author":"Zhou","year":"2019","journal-title":"Her. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.3760\/cma.j.issn.1007-1245.2021.08.030","article-title":"Effect of Shensong Yangxin Capsules on myocardial ischemia and P-wave dispersion in patients with hypertension complicated by persistent atrial fibrillation","volume":"27","author":"Zhou","year":"2021","journal-title":"Int. Med. Health Guid News"},{"key":"B50","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3969\/j.issn.1671-6450.2017.03.019","article-title":"Preventive effect of Shensong Yangxin Capsule on recurrence after radiofrequency ablation for atrial fibrillation","volume":"16","author":"Zhuo","year":"2017","journal-title":"J. Diffic. Compl Cas."},{"key":"B51","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2147\/clep.S47385","article-title":"Epidemiology of atrial fibrillation: European perspective","volume":"6","author":"Zoni-Berisso","year":"2014","journal-title":"Clin. Epidemiol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1620340\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T05:46:19Z","timestamp":1750225579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1620340\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":51,"alternative-id":["10.3389\/fphar.2025.1620340"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1620340","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"article-number":"1620340"}}